https://www.firdapsehcp.com/

Contact Information:

Frank A. Perez, M.A.
Regional Account Manager
Cell:  719-649-1754
fperez@catalystpharma.com

Tara Moreton
Regional Account Manager
Cell: 407-230-4437
tmoreton@catalystpharma.com

Luke Krosky
Regional Account Manager
Cell: 913-486-0876
lkrosky@catalystpharma.com
 

ZOOM meeting link. Available 30 minutes pre-conference, during all breaks as noted on the program and 30 minutes post adjournment to address all questions and provide information. 

Virtual Exhibit Hall Home

FIRDAPSE is the first and only FDA-approved, evidence-based therapy indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.1,2

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE:

FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

CONTRAINDICATIONS

FIRDAPSE is contraindicated in patients with:

• A history of seizures
• Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS

Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.

Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.

ADVERSE REACTIONS

The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.

Please see full Prescribing Information for additional Important Safety Information.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.

FIRDAPSE Brochure

LEMS Disease Brochure

LEMS v. MG Infographic